Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Octreotide for Post-EMR Bleeding
NCT02032784Phase 4Terminated
- Sponsor
- AdventHealth
- Start
- Mar 2014
- Primary completion
- Jun 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Octreotide long-acting injection in Duodenal adenoma (DA) and ampullary adenoma (2 arms), sponsored by AdventHealth. Primary endpoint: Post endoscopic mucosal resection bleeding at 3 days. Started Mar 2014; status: terminated.
02
Drugs
Octreotide long-acting injection
03
Conditions
Duodenal adenoma (DA)ampullary adenoma
Beyond the preview
Go deeper on NCT02032784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02032784.